Table 3.
Comparison of anti-SARS-Cov-2 antibody seroprevalence and the prevalence of confirmed COVID-19 cases in five prefectures
| SARS-Cov-2 antibody seroprevalence |
[B]
Prevalence of COVID-19 based on Government Report of confirmed cases (%) |
Ratio
[A]/[B] |
|||
|
| |||||
| Study | Prefecture |
Sample Size
N |
[A]
Seroprevalence of anti-SARS-CoV-2 antibodies (Roche & Abbott Positive) N (%) |
||
| Results from the MHLW random sampling study (Dec 2020) |
Tokyo | 3,399 | 31 (0.91) | 0.32* | 2.9 |
| Osaka | 2,746 | 16 (0.58) | 0.26* | 2.2 | |
| Miyagi | 2,860 | 14 (0.14) | 0.06* | 2.5 | |
| Aichi | 2,960 | 16 (0.54) | 0.15* | 3.6 | |
| Fukuoka | 3,078 | 6 (0.19) | 0.12* | 1.6 | |
|
| |||||
| Results from this study (Jan-Feb 2021) |
Hiroshima | 2,351 | 5 (0.21) | 0.17** | 1.2 |
MHLW, Ministry of Health, Labour and Welfare of Japan
*Based on Japanese government report of confirmed COVID-19 cases on December 7, 2021
**Based on Japanese government report of confirmed COVID-19 cases on January 31, 2021